To use all functions of this page, please activate cookies in your browser.
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Sodium acetrizoate
Sodium acetrizoate (rINN, trade names Urokon, Triurol and Salpix), the sodium salt of acetrizoic acid, is a high-osmolality, water-soluble, iodine-based radiographic contrast medium no longer in clinical use.[1] Additional recommended knowledgeAcetrizoate was developed by V.H. Wallingford of Mallinckrodt, and introduced in 1950;[2] it was employed as a contrast agent for several radiographic studies, including pyelography,[3][4] angiography of the brain, carotid arteries and the aorta,[5][6] and cholecystography.[7][8] It was soon found to be highly toxic to the kidneys and nervous system—work urging caution in its administration was published as early as 1959,[9] after reports of adverse reactions ranging from hypersensitivity to brain damage—and was eventually replaced by other agents with higher efficacy and lower toxicity, such as sodium diatrizoate, a closely related compound.[2] References
Categories: Organoiodides | Radiocontrast agents |
||||||||||||||||||||||||||||||||||||||||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Sodium_acetrizoate". A list of authors is available in Wikipedia. |